Medication info
Amoratanal Tablets 5/160/10 Milligrams

Amoratanal Tablets 5/160/10 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.94mg / 1 tabletValsartan›160mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
CMG Pharmaceutical Co., Ltd.
Appearance
Pale orange oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202108062 · Approved 2021.12.21 · Insurance code 648604360

Summary

Main use
Treats hypertension, improves dyslipidemia, and inhibits the progression of atherosclerosis and the risk of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water. If possible, it is recommended to take it at the same time each day (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. Patients taking an amlodipine/valsartan combination and rosuvastatin as separate products may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher); however, do not administer the amlodipine/valsartan combination to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Older adults aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal failure: No dose adjustment is necessary in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Use particular caution when administering rosuvastatin 20mg to patients with moderate renal failure. 4. Patients with hepatic failure: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of a 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of a 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
CMG Pharmaceutical Co., Ltd.

Efficacy & effects

Treats hypertension, improves dyslipidemia, and inhibits the progression of atherosclerosis and the risk of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of premature coronary artery disease
View approved original text

This medication is used for patients who need to manage both hypertension and hypercholesterolemia simultaneously. Amlodipine and valsartan help effectively lower blood pressure in patients with essential hypertension who find it difficult to control blood pressure with monotherapy. Rosuvastatin is used as an adjunct for patients with primary hypercholesterolemia and dyslipidemia who are not controlled by diet and exercise. It also slows the progression of atherosclerosis and reduces risks associated with cardiovascular diseases, stroke, myocardial infarction, and arterial revascularization procedures. Therefore, this combination medication is used to improve cardiovascular health by managing both blood pressure and blood lipid levels.

How to take

Adult dose

Take 1 tablet once daily with water. If possible, it is recommended to take it at the same time each day (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. Patients taking an amlodipine/valsartan combination and rosuvastatin as separate products may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher); however, do not administer the amlodipine/valsartan combination to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Older adults aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal failure: No dose adjustment is necessary in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Use particular caution when administering rosuvastatin 20mg to patients with moderate renal failure. 4. Patients with hepatic failure: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of a 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of a 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This medication can cause serious harm to the fetus during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately once pregnancy is confirmed. Patients with allergies to any of the components of this medication, severe liver impairment, kidney impairment, pregnant or breastfeeding women should not take this medication. Patients with fluid or sodium depletion, hyperkalemia, renal artery stenosis, etc., should ensure their condition is well checked before using this medication. Patients with heart failure, myocardial infarction, aortic stenosis, or history of angioedema require careful management when taking this medication. This medication may cause muscle-related side effects such as myalgia, myopathy, and rarely rhabdomyolysis, so should inform medical staff if muscle pain or weakness occurs. Dizziness or fatigue may occur during driving or operating machinery, so caution is needed. This medication may interact with several other medications, so if you are taking other medications, you must inform medical staff, especially if taking potassium-sparing diuretics, antihyperlipidemic agents, and immunosuppressants. It is advisable not to take this medication while breastfeeding, and if it is necessary, breastfeeding should be stopped. Elderly patients may be more sensitive to this medication, so it is recommended to start with a lower dose and carefully increase. Overdose of this medication can lead to severe symptoms such as hypotension and shock, so immediate medical attention should be sought, and emergency treatment may be necessary.

Side effects

  • Peripheral edema
  • heat sensation
  • increased ALT
  • increased AST
  • increased blood creatinine
  • flank pain
  • neck pain
  • dizziness
  • sensory loss
  • nasopharyngitis
Show 178 more
  • rash
  • nasopharyngitis
  • influenza
  • hypersensitivity
  • visual impairment
  • anxiety
  • headache
  • drowsiness
  • orthostatic dizziness
  • paresthesia
  • vertigo
  • tinnitus
  • tachycardia
  • palpitations
  • syncope
  • orthostatic hypotension
  • hypotension
  • cough
  • pharyngeal and laryngeal pain
  • diarrhea
  • nausea
  • abdominal pain
  • constipation
  • thirst
  • erythema
  • sweating
  • rash
  • itching
  • joint swelling
  • low back pain
  • arthritis
  • muscle cramps
  • lethargy
  • polyuria
  • nocturia
  • erectile dysfunction
  • edema
  • lymphoedema
  • facial edema
  • fatigue
  • flushing
  • weakness
  • facial flushing
  • chest pain
  • pain
  • enuresis
  • chest discomfort
  • abdominal discomfort
  • gastroesophageal reflux disease
  • hypercholesterolemia
  • hypoglycemia
  • thrombocytopenia
  • leukopenia
  • allergic reaction
  • hyperglycemia
  • insomnia
  • mood changes
  • tremors
  • taste disturbance
  • peripheral neuropathy
  • hypertonia
  • arrhythmia
  • bradycardia
  • atrial fibrillation
  • ventricular tachycardia
  • vasculitis
  • dyspnea
  • rhinitis
  • vomiting
  • dyspepsia
  • pancreatitis
  • gastritis
  • gingival hyperplasia
  • hepatitis
  • jaundice
  • alopecia
  • purpura
  • skin depigmentation
  • photosensitivity reaction
  • angioedema
  • urticaria
  • erythema multiforme
  • Stevens-Johnson syndrome
  • myalgia
  • urination disorders
  • enuresis
  • gynecomastia
  • pain
  • malaise
  • weight loss
  • weight gain
  • decreased hemoglobin
  • decreased hematocrit
  • neutropenia
  • serum sickness
  • increased serum potassium
  • vasculitis
  • vesicular dermatitis
  • renal failure
  • kidney damage
  • insomnia
  • decreased libido
  • pharyngitis
  • rhinitis
  • sinusitis
  • upper respiratory tract infection
  • viral infection
  • intestinal vascular edema
  • polyneuropathy
  • amnesia
  • peripheral neuropathy
  • thrombocytopenia
  • lupus-like syndrome
  • muscle rupture
  • immune-mediated necrotizing myopathy
  • hematuria
  • depression
  • sleep disorders
  • interstitial lung disease
  • sexual dysfunction
  • gynecomastia
  • fatal and non-fatal liver failure
  • memory decline
  • forgetfulness
  • amnestic syndrome
  • memory impairment
  • confusion
  • myasthenia gravis
  • ocular myasthenia
  • increased CK
  • constipation
  • oral hemorrhage
  • vomiting
  • insulin-dependent diabetes mellitus
  • diabetes complications
  • leg fracture
  • spinal fracture
  • fracture
  • skin mass
  • second-degree atrioventricular block
  • vestibular neuritis
  • retinal detachment
  • unspecified skin tumor-like condition
  • shingles
  • herniated disc
  • laceration
  • hemoptysis
  • sputum disease
  • tonsillitis
  • bronchitis
  • paresthesia
  • hoarseness
  • gastroesophageal reflux
  • diverticulitis
  • stomatitis
  • carpal tunnel syndrome
  • chills
  • facial flushing
  • increased blood sugar
  • increased triglycerides
  • hypercholesterolemia
  • increased blood pressure
  • exacerbation of hypertension
  • neck/shoulder pain
  • toe fracture
  • osteomyelitis
  • skin infection
  • unspecified skin inflammation
  • localized skin reaction
  • palpitations
  • exacerbation of angina
  • auditory disturbances
  • overactive bladder
  • increased blood creatinine
  • vitreous detachment
  • prostatomegaly
  • acute renal failure
  • oliguria

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius to preserve its effectiveness and safety.

Appearance and packaging

Appearance

Pale orange oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.